Icon
+91 94997 68112
Login Register

Crexont - (35 mg/140 mg, 52.5 mg/210 mg, 70 mg/280 mg, 87.5 mg/350 mg ; Extended-release Capsules)

Carbidopa and Levodopa Impax
35 mg/140 mg, 52.5 mg/210 mg, 70 mg/280 mg, 87.5 mg/350 mg ; Extended-release Capsules
Less Than $1000 mn
None None
None None
None None
CREXONT is a combination of carbidopa (an aromatic amino acid decarboxylation inhibitor) and levodopa (an aromatic amino acid) indicated for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication in adults.
Yes
Crexont Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11 Patent 12
******* *******
  1. *** **, **** : * **** ** ** ***** *** ***** ** *** ***.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.